Cardiol Therapeutics Inc. (TSE:CRDL) has released an update.
Cardiol Therapeutics Inc. has achieved key milestones in its clinical trials for heart disease treatments, completing enrollment for its MAvERIC-Pilot study in recurrent pericarditis and surpassing 50% enrollment in the ARCHER trial for acute myocarditis. The company’s financial health appears robust, with sufficient cash reserves to fund operations into 2026. Promising pre-clinical data showcased at various scientific sessions in 2023 supports the potential of Cardiol’s drug candidates in treating heart disease.
For further insights into TSE:CRDL stock, check out TipRanks’ Stock Analysis page.
